?? Brain Health Innovations ??

MERCK SHARP & DOHME LLC invented the novel compounds of the structural Formula (I), and the pharmaceutically acceptable salts thereof are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease. Parkinson's Disease and traumatic brain injury. Publication Number WO/2024/137319

BRAIN BIOTECH AG invented a microorganism - ?Bacillus subtilis DSM-No. 402. - , or spore thereof, capable of forming a metabolic biofilm is disclosed. Also, compositions, methods and uses of the microorganism, or spore thereof, are disclosed. Publication Number WO/2024/133812

NeuroDerm, Ltd. invented levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formulations may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed prodrugs and/or liquid pharmaceutical formulations. Application Number 18549452

CYBERMEDIC CO., LTD. Invented a multimodal cranial nerve stimulation treatment system for personalized optimal rehabilitation.

Washington University, The Regents of the University of Michigan, Emory University systems and methods for individualized targeting of deep brain stimulation (DBS). In addition, methods for monitoring the treatment of a subject using a DBS system are described.

Application Number 18526386

NATIONAL TAIWAN UNIVERSITY invented an automatic calculation method of gray-to-white-matter ratio for head computed tomography of patients with cardiac arrest is disclosed and includes an image registration step, a K-means segmentation step, a segmentation refinement step and a GWR calculation step.?

Application Number 18393588

SINON NANO SCIENCES, INC. invented PH-base structural change of water soluble carbon nanoparticles for encapsulation and release of therapeutic agents in biological systems.

Application Number 18419231

NEURO DEVICE GROUP S.A.?a neural stimulation system (100) for supporting speech and/or language skills of a user?

Publication Number WO/2024/133794

The Regents of the University of California invented a tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

Application Number 18554762

SINTALICA S.R.L. invented the novel non-hallucinogenic tryptamine compounds of formula I and/or formula II:. Compounds of formula I or II can be obtained by a process comprising a conjugation step of a non-hydrolysable chemical moiety with tryptamine precursors, which can be obtained synthetically, and which are analogue to tryptamines naturally occurring in psilocybin containing mushrooms, preferably in psilocybin containing mushrooms belonging to the Psilocybe genus. The conjugated non-hydrolysable chemical moiety allows to reduce or to prevent the crossing of the blood brain barrier (BBB). The invention also relates to a composition comprising at least one of said non-hallucinogenic tryptamine compounds of formula I and/or formula II, optionally in combination with at least one monoamine oxidase inhibitor (MAOI) compound and/or with at least one antioxidant selected from carotenoids. Lastly, the invention relates to the pharmaceutical uses of the compounds according to formula I and/or II and to the pharmaceutical uses of the composition of the invention.

Publication Number WO/2024/134619

AcroViz USA Inc. and Taipei Medical University invented the method of predicting a brain atrophy condition for an individual using the individual's predicted age difference (PAD). The method comprises acquiring at least one brain image of the individual; processing the brain image to obtain at least one feature of the brain image; generating a PAD value of the individual based on the at least one feature of the image; and determining a brain atrophy condition of the individual based on the PAD value. Application Number 18539555

SCIENTIA VASCULAR, INC. invented the?intravascular devices for navigating tortuous vascular environments like the human brain. Application Number 18391400